



Pfizer Limited

The Capital, 1802/1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

January 31, 2025

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai – 400 001
Scrip Code: 500680

The Manager, Listing Dept.
The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block Bandra-Kurla Complex, Bandra (E)
Mumbai – 400 051
Scrip Symbol: PFIZER

Dear Sirs,

Sub: Outcome of the Board Meeting- Unaudited Financial Results for the quarter and nine months ended December 31, 2024.

Ref.: Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”).

Pursuant to the Regulation 33 of the Listing Regulations, we submit herewith the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024, which were approved by the Board of Directors of the Company at their Meeting held today, that commenced at 2.30 p.m. and concluded at 4.00 p.m.

Also please find enclosed herewith the Limited Review Report issued by Statutory Auditors namely, B S R & Co. LLP in respect of the said Unaudited Financial Results.

We request you to kindly take the same on record.

Thanking you,

Yours truly,

For Pfizer Limited

Prajeet Nair

Director – Corporate Services & Company Secretary

**Cc.: National Securities Depository Limited (NSDL)
Central Depository Services (India) Limited (CDSL)
KFin Technologies Limited**



Pfizer Limited

The Capital, 1802/1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

Statement of Unaudited Financial Results for the Quarter and Nine months ended 31 December 2024

(₹ in crore except earnings per share)

Particulars	3 months ended 31/12/2024	Preceding 3 months ended 30/09/2024	Corresponding 3 months ended in the previous year 31/12/2023	Year to date figures for nine months ended 31/12/2024	Year to date figures for nine months ended 31/12/2023	Previous year ended 31/03/2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income						
(a) Revenue from operations	537.99	588.59	539.97	1,689.44	1,646.54	2,193.17
(b) Other income	42.76	43.07	35.85	127.67	105.38	180.51
Total income	580.75	631.66	575.82	1,817.11	1,751.92	2,373.68
2 Expenses						
(a) Cost of materials consumed	67.31	76.65	77.23	201.70	247.12	335.80
(b) Purchases of stock-in-trade	104.99	80.65	148.60	373.23	374.63	468.59
(c) Changes in inventory of finished goods, work-in-progress and stock-in-trade	24.26	53.42	(43.27)	33.04	(18.52)	(11.82)
(d) Employee benefits expense	96.29	100.76	89.37	288.42	272.69	347.80
(e) Finance costs	1.51	2.10	2.86	5.72	8.46	15.41
(f) Depreciation and amortization expense	14.80	14.99	17.55	44.39	48.53	62.28
(g) Other expenses	99.15	87.86	115.49	280.32	324.75	417.50
Total expenses	408.31	416.43	407.83	1,226.82	1,257.66	1,635.56
3 Profit before tax and exceptional items (1 - 2)	172.44	215.23	167.99	590.29	494.26	738.12
4 Exceptional items (Refer Note 5)	-	-	7.95	-	7.95	7.95
5 Profit before tax (3 + 4)	172.44	215.23	175.94	590.29	502.21	746.07
6 Tax expense						
(a) Current tax	50.10	59.89	29.17	165.04	109.94	158.92
(b) Deferred tax	(5.26)	(3.01)	16.79	(11.41)	19.80	36.11
(c) Tax adjustments for earlier years	-	-	-	-	-	(0.29)
7 Net profit for the period / year (5 - 6)	127.60	158.35	129.98	436.66	372.47	551.33
8 Other comprehensive income						
(a) Items that will not be reclassified subsequently to profit or loss	(0.72)	(0.71)	(1.11)	(2.15)	(3.31)	7.28
(b) Income tax related to items that will not be reclassified to profit or loss	0.18	0.18	0.28	0.54	0.83	(1.83)
Other comprehensive income, net of taxes	(0.54)	(0.53)	(0.83)	(1.61)	(2.48)	5.45
9 Total comprehensive income for the period / year (7 + 8)	127.06	157.82	129.15	435.05	369.99	556.78
10 Paid-up equity share capital (Face value per share ₹10)	45.75	45.75	45.75	45.75	45.75	45.75
11 Other equity						3,549.79
12 Earnings per share - Basic and Diluted (of ₹10/- each) #						
Computed on the basis of net profit for the period / year	27.89	34.61	28.42	95.44	81.42	120.51
# Earnings per share - Basic and Diluted before Exceptional items	27.89	34.61	27.12	95.44	80.12	119.22

*Not annualised

CIN: L24231MH1950PLC008311
Email ID: contactus.india@pfizer.com
Website: www.pfizerindia.co.in

M. Kumar

NOTES:

1. The above financial results were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on January 31, 2025.
2. The standalone financial results of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time).
3. The Company does not have any subsidiary company or associate company or joint venture company as at December 31, 2024.
4. The financial results for the quarter and nine months ended December 31, 2024 have been subject to Limited Review by the Statutory Auditors of the Company. The Limited Review report does not contain any modifications. The Limited Review report will be filed with the Stock Exchanges and will also be available on the Company's website - www.pfizerltd.co.in
5. Exceptional item for the quarter and nine months ended December 31, 2023 and year ended March 31, 2024 is in relation to provision for old pending VAT / CST litigations. The Company opted for Maharashtra VAT Amnesty Scheme for certain years and had received final settlement orders. Pursuant to the said orders, the Company had written back excess provision of ₹ 7.95 crore.
6. The Company had intended to transfer its unexpired leasehold rights in the Maharashtra Industrial Development Corporation ("MIDC") Land and Sale of Buildings constructed on such land at Thane and accordingly, it was classified as 'Asset held for sale'. During the quarter ended December 31, 2023, the Company had entered into an Agreement to Assign and Assume the Lease of MIDC Land and Sale of Buildings constructed on such land to Zoetis Pharmaceutical Research Private Limited, for a lumpsum consideration of ₹ 264.40 crore, of which ₹ 52.88 crore was received as an advance. During the quarter ended December 31, 2024, the Company has received a direction from MIDC to pay charges towards transfer and to comply with certain conditions. Completion of transaction is subject to the final approval from MIDC and hence effect of the said agreement has not been given in these financial results.
7. The Company has only one segment which is 'Pharmaceuticals'. Therefore, disclosure relating to segments is not applicable and accordingly not made.

January 31, 2025

For Pfizer Limited



Meenakshi Nevatia
Managing Director

B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing
Nesco IT Park 4, Nesco Center
Western Express Highway
Goregaon (East), Mumbai – 400 063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited financial results of Pfizer Limited for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Pfizer Limited

1. We have reviewed the accompanying Statement of unaudited financial results of Pfizer Limited (hereinafter referred to as "the Company") for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Sadashiv Shetty

Partner

Mumbai

31 January 2025

Membership No.: 048648

UDIN:25048648BMNYHC1291